Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Head-to-Head Comparison of Thymoglobulin vs. Campath-1H vs. Our Standard Center Treatment Protocol in Living Donor Renal Transplantation - A Study to Evaluate the Avoidance of Long-Term Nephrotoxic Calcineurin Inhibitor Therapy
Brief Summary: To observe in a randomized prospective pilot study the effectiveness and toxicity of Thymoglobulin vs. Campath-1H used for induction therapy in recipients of living donor (LD) kidneys, compared with our standard treatment protocol of Zenapax® and maintenance immunosuppression


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Thymoglobulin | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Campath-1H | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Daclizumab | Intervention Type: DRUG; Name: Thymoglobulin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Campath-1H; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Daclizumab; Assigned to Arm(s): C
B: Arm Label: Campath-1H 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Alemtuzumab | Arm Label: Tacrolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tacrolimus | Arm Label: Campath-1H 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Alemtuzumab | Intervention Type: DRUG; Name: Alemtuzumab; Assigned to Arm(s): Campath-1H 20 mg | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): Tacrolimus | Intervention Type: DRUG; Name: Alemtuzumab; Assigned to Arm(s): Campath-1H 30 mg
C: Arm Label: Alemtuzumab High-Risk Patients; Type: EXPERIMENTAL; Interventions: Drug: tacrolimus, Drug: alemtuzumab, Drug: mycophenolate mofetil, Drug: steroids | Arm Label: Conventional High-Risk Patients; Type: ACTIVE_COMPARATOR; Interventions: Drug: rabbit anti-thymocyte globulin, Drug: tacrolimus, Drug: mycophenolate mofetil, Drug: steroids | Arm Label: Alemtuzumab Low- Risk Patients; Type: EXPERIMENTAL; Interventions: Drug: tacrolimus, Drug: alemtuzumab, Drug: mycophenolate mofetil, Drug: steroids | Arm Label: Conventional Low-Risk Patients; Type: ACTIVE_COMPARATOR; Interventions: Drug: basiliximab, Drug: tacrolimus, Drug: mycophenolate mofetil, Drug: steroids | Intervention Type: DRUG; Name: basiliximab; Assigned to Arm(s): Conventional Low-Risk Patients | Intervention Type: DRUG; Name: rabbit anti-thymocyte globulin; Assigned to Arm(s): Conventional High-Risk Patients | Intervention Type: DRUG; Name: tacrolimus; Assigned to Arm(s): Alemtuzumab High-Risk Patients, Alemtuzumab Low- Risk Patients, Conventional High-Risk Patients, Conventional Low-Risk Patients | Intervention Type: DRUG; Name: alemtuzumab; Assigned to Arm(s): Alemtuzumab High-Risk Patients, Alemtuzumab Low- Risk Patients | Intervention Type: DRUG; Name: mycophenolate mofetil; Assigned to Arm(s): Alemtuzumab High-Risk Patients, Alemtuzumab Low- Risk Patients, Conventional High-Risk Patients, Conventional Low-Risk Patients | Intervention Type: DRUG; Name: steroids; Assigned to Arm(s): Alemtuzumab High-Risk Patients, Alemtuzumab Low- Risk Patients, Conventional High-Risk Patients, Conventional Low-Risk Patients
D: Arm Label: Group 1 Standard Immunosuppression; Type: N/A; Interventions: N/A | Arm Label: Group 2 Campath Immunosuppression; Type: N/A; Interventions: N/A

Answer: A